Previously, we discovered and optimized the first small-molecule CHD1L inhibitors (CHD1Li), which are allosteric inhibitors of the ATPase activity of CHD1L, inducing the reversion of EMT and cell death in colorectal cancer and display antitumor activity in vivo [16,17]. The gene discussed is CHD1L; the disease is colorectal cancer.